- Home
- BODI vs PRLD Comparison
BODI vs PRLD Comparison
Compare BODI & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BODI | PRLD |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 69.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BODI | PRLD |
|---|---|---|
| Price | $11.21 | $1.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $8.00 | $4.00 |
| AVG Volume (30 Days) | 104.0K | ★ 446.7K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,565,000.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 250.00 |
| 52 Week Low | $3.38 | $0.61 |
| 52 Week High | $12.33 | $4.22 |
Technical Indicators
Market Signals| Indicator | BODI | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 58.87 |
| Support Level | $10.18 | $1.60 |
| Resistance Level | $12.33 | $1.72 |
| Average True Range (ATR) | 0.99 | 0.17 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 69.21 | 73.71 |
Price Performance
Historical ComparisonAbout BODI The Beachbody Company Inc.
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.